Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

被引：9
|
作者：
Chi, Y. [1 ]
Gao, M. [2 ]
Zhang, Y. [3 ]
Shi, F. [4 ]
Cheng, Y. [5 ]
Guo, Z. [6 ]
Ge, M. [7 ]
Qin, J. [8 ]
Zhang, J. [9 ]
Li, Z. [10 ]
Zhou, X. [11 ]
Huang, R. [12 ]
Chen, X. [13 ]
Liu, H. [14 ]
Cheng, R. [15 ]
Xu, Z. [16 ]
Zheng, X. [2 ]
Li, D. [2 ]
Tang, P. [17 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Tianjins Clin Res Ctr Canc, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin, Peoples R China
[3] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Head & Neck Surg Dept,Jiangsu Canc Hosp, Nanjing, Peoples R China
[4] Hunan Canc Hosp, Nucl Med Ctr, Thyroid Tumour Internal Med Dept, Changsha, Peoples R China
[5] Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Head & Neck Surg, Guangzhou, Peoples R China
[7] Chinese Acad Sci, Head & Neck Surg Inst Canc & Basic Med ICBM, Canc Hosp,Univ Chinese Acad Sci,Zhejiang Canc Hos, Zhejiang Prov Peoples Hosp,Peoples Hosp,Hangzhou, Hangzhou, Peoples R China
[8] Zhengzhou Univ, Affiliated Canc Hosp, Thyroid & Head & Neck Surg, Henan Canc Hosp, Zhengzhou, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Thyroid Surg Ward, Harbin, Peoples R China
[10] China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Dept Head & Neck Surg, Shenyang, Peoples R China
[11] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Head & Neck Surg, Chongqing, Peoples R China
[12] Sichuan Univ, West China Hosp, Nucl Med, Chengdu, Peoples R China
[13] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China
[14] Fujian Canc Hosp, Head & Neck Dept, Fuzhou, Peoples R China
[15] Kunming Med Univ, Affiliated Hosp 1, Dept Thyroid Surg, Kunming, Yunnan, Peoples R China
[16] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Head & Neck Surg,Natl Canc Ctr, Beijing, Peoples R China
[17] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept VIP,Natl Canc Ctr, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA88
引用
收藏
页码：S1215 / S1215
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of STUPP Regimen Anlotinib for Newly Diagnosed Glioblastoma: A Multicenter, Double-Blind, Randomized Phase II Trial
    Chen, Y.
    Liu, G.
    Sun, P.
    Li, M.
    Yang, X.
    Pan, L.
    Wang, L.
    Hua, Y.
    Zhao, M.
    Liu, Y.
    Ran, J.
    Cai, H.
    Lu, X.
    Hao, J.
    Li, X.
    Zheng, W.
    Liu, Z.
    Lin, S.
    Deng, M.
    Yang, Q.
    Guo, C.
    Li, J.
    Chen, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E223 - E224
  • [22] Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)
    Lin, Y.
    Yang, H.
    Shi, F.
    Yang, A.
    Han, X.
    Liu, B.
    Li, Z.
    Ji, Q.
    Tang, L.
    Deng, Z.
    Ding, Y.
    Fu, W.
    Xie, X.
    Li, L.
    He, X.
    Lv, Z.
    Wu, L.
    Liu, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1294 - S1294
  • [23] Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
    Kim, Mijin
    Kim, Tae Hyuk
    Shin, Dong Yeob
    Lim, Dong Jun
    Kim, Eui Young
    Kim, Won Bae
    Chung, Jae Hoon
    Shong, Young Kee
    Kim, Bo Hyun
    Kim, Won Gu
    Jeon, Minji
    Kim, Tae Yong
    Kim, Sun Wook
    Jo, Young Suk
    Lee, Eun-Jig
    Kim, Min-Hee
    Kang, Moo Il
    Jang, Eun Kyung
    Kim, In Joo
    THYROID, 2018, 28 (03) : 340 - 348
  • [24] EFFICACY AND SAFETY OF STUPP REGIMEN WITH OR WITHOUT ANLOTINIB FOR NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED PHASE II TRIAL
    Chen, Y.
    Liu, G.
    Sun, P.
    Li, M.
    Yang, X.
    Pan, L.
    Wang, L.
    Hua, Y.
    Zhao, M.
    Liu, Y.
    Ran, J.
    Cai, H.
    Lu, X.
    Jiang, H.
    Li, X.
    Zheng, W.
    Liu, Z.
    Lin, S.
    Deng, M.
    Yang, Q.
    Guo, C.
    Li, J.
    Chen, Z.
    NEURO-ONCOLOGY, 2024, 26
  • [25] Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.
    Neoptolemos, John P.
    Palmer, Daniel
    Greenhalf, William
    Ghaneh, Paula
    Jackson, Richard
    Evans, Anthony
    Shaw, Victoria
    Wadsley, Jonathan
    Valle, Juan W.
    Wasan, Harpreet
    Falk, Stephen
    Cunningham, David
    Coxon, Fareeda Y.
    Ross, Paul J.
    Wadd, Nick
    Hickish, Tamas
    Costello, Eithne
    Campbell, Fiona
    Rawcliffe, Charlotte
    Middleton, Gary William
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
    Bible, Keith C.
    Suman, Vera J.
    Molina, Julian R.
    Smallridge, Robert C.
    Maples, William J.
    Menefee, Michael E.
    Rubin, Joseph
    Sideras, Kostandinos
    Morris, John C., III
    McIver, Bryan
    Burton, Jill K.
    Webster, Kevin P.
    Bieber, Carolyn
    Traynor, Anne M.
    Flynn, Patrick J.
    Goh, Boon Cher
    Tang, Hui
    Ivy, Susan Percy
    Erlichman, Charles
    LANCET ONCOLOGY, 2010, 11 (10): : 962 - 972
  • [27] Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.
    Chi, Yihebali
    Gao, Ming
    Zhang, Yuan
    Shi, Feng
    Cheng, Ying
    Guo, Zhuming
    Ge, Minghua
    Qin, Jianwu
    Zhang, Jiewu
    Li, Zhendong
    Zhou, Xiaohong
    Huang, Rui
    Chen, Xiaohong
    Liu, Hui
    Cheng, Ruochuan
    Xu, Zhengang
    Zheng, Xiangqian
    Li, Dapeng
    Tang, Pingzhang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
    Cui, Chuanliang
    Mao, Lili
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Li, Siming
    Lian, Bin
    Gu, Kangsheng
    Tao, Min
    Song, Xin
    Lin, Tongyu
    Ren, Xiubao
    Qin, Shukui
    Guo, Jun
    MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
  • [29] A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
    Brose, M. S.
    Panaseykin, Y.
    Konda, B.
    de la Fouchardiere, C.
    Hughes, B. G. M.
    Gianoukakis, A. G.
    Park, Y. J.
    Romanov, I.
    Krzyzanowska, M. K.
    Binder, T.
    Dutcus, C.
    Xie, R.
    Taylor, M. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1409 - S1409
  • [30] Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
    Brose, Marcia S.
    Nutting, Christopher M.
    Sherman, Steven I.
    Shong, Young Kee
    Smit, Johannes W. A.
    Reike, Gerhard
    Chung, John
    Kalmus, Joachim
    Kappeler, Christian
    Schlumberger, Martin
    BMC CANCER, 2011, 11
12345